ArticleJournal of gastrointestinal oncology2025
Development and validation of a GP73-based predictive model for the diagnosis of early-stage hepatocellular carcinoma.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) has become a major global public health concern due to its high incidence, high mortality, and frequent diagnosis at advanced stages. Currently available biomarkers, such as alpha-fetoprotein (AFP), have limited sensitivity and specificity for early-stage HCC, making early screening a significant challenge. Therefore, identifying novel and complementary biomarkers is essential to improve early detection rates and patient prognosis. Golgi protein-73 (GP73) is a secreted glycoprotein that is highly expressed in various malignancies and can be released into the bloodstream. Herein, we evaluated its potential value for early diagnosis of HCC. Methods: This retrospective cross-sectional study aimed to evaluate the diagnostic value of serum GP73 for early-stage HCC. A total of 401 patients were included in the study, comprising 63 patients with early-stage HCC and 338 patients with liver cirrhosis. Diagnoses of HCC and cirrhosis were confirmed based on a combination of imaging, pathological findings, and clinical guidelines. Serum levels of GP73 and AFP were measured using enzyme-linked immunosorbent assay (ELISA), and other clinical variables such as age and prothrombin time (PT) were obtained from medical records. Results: The area under the curve (AUC) for AFP and GP73 alone in diagnosing early-stage HCC was 0.769 [95% confidence interval (CI): 0.700-0.838] and 0.627 (95% CI: 0.539-0.716), respectively. After adjustment in multivariate analysis, GP73 remained an independent diagnostic factor (P<0.05). The developed nomogram achieved corrected C-indexes of 0.812 and 0.918 in the training and validation cohorts, respectively. Among patients infected with hepatitis B virus (HBV), the nomogram demonstrated AUCs of 0.836 in the training cohort and 0.900 in the validation cohort, indicating good discriminative ability. Baseline characteristics were comparable between the groups. Conclusions: The nomogram model proposed in this study, which integrates GP73, AFP, age, and PT, may serve as a simple, intuitive, and customizable clinical tool for identifying early-stage HCC among patients with liver cirrhosis. The model exhibits high diagnostic performance, especially in HBV-related populations, and shows promising potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.